Multiple myeloma is a rare,
malignant plasma cell cancer affecting the bone marrow and other blood producing organs.
PEL gene expression closely resembles that of
malignant plasma cells, including the low expression of mature B cell genes.
Similar to
malignant plasma cells, all PEL samples tested express the vitamin D receptor and are sensitive to the vitamin D analogue drug EB 1089 (Seocalcitol).
Unlike normal plasma cells,
the malignant plasma cells look large and round with a high mitotic index (measure of the proliferation of a cell population) in early stages of cellular differentiation.
Not exact matches
In multiple myeloma, normal
plasma cells transform into
malignant myeloma
cells and produce large quantities of toxic abnormal immunoglobulin called monoclonal protein that can damage multiple organs.
When
plasma cells become
malignant, they affect healthy blood
cell production, which weakens the immune system.
Our group has 3 major goals: Develop novel therapeutic approaches based on centrosomal clustering To further develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-
malignant, asymptomatic to
malignant, symptomatic stages of
plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel targets Translate small molecule therapeutics from bench to clinical trials To evaluate novel agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus on multiple myeloma